Dr. Clay Siegall Joins Mirna Therapeutics

Three years ago, Mirna Therapeutics, a biotechnology company announced that it was going to appoint Clay Siegall, the CEO and co-founder of Seattle Genetics to become a member of its board of directors. Clay Siegall will be operating as the CEO of the company.

Mirna Therapeutics is based in Texas, and it was started in 2007. The institution mostly focuses in microRNA therapeutics. The main objective of the biotechnology company is to come up with better cancer treatment. Dr. Clay has a lot of experience in cancer research, and his skills will help the institution in its plans. According to the CEO of Mirna Therapeutics, Dr. Paul Lammers, the company is very excited to have Siegall in its board. With his skills, the company is confident that they will be able to achieve their goals in advancing microRNA based therapeutics.

Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.

Dr. Clay Siegall is one of the most respected individuals in the biotechnology industry. He started Seattle Genetics back in 2008, and he serves as the CEO and president of the company. He is also the chairman in the institution’s board of directors. Under his leadership, Seattle Genetics has managed to create good antibody therapies to help individuals struggling with cancer. He is also a well -known author, and he has published over 70 works.

Before starting his company, Dr. Clay was attending school at the University of Maryland. He graduated with a bachelor’s degree in Zoology. He also went to the George Washington University, and that’s where he got his PhD in Genetics. After completing his education, he was appointed to work for the National Cancer Institute and several other health institutions in the world.

Seattle Genetics has become one of the leading biotechnology companies in the world. The company has successfully developed clinical and other preclinical products. The first product from the company was introduced in the market several years ago, and it has done quite well. More drugs from the company are being developed, and before the end of the year, more drugs will be introduced by the institution. The company recently announced that it was planning to hire more professionals to help in the projects.

More about Clay Siegall: